|
Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600–mutant pediatric low-grade glioma (pLGG). |
| |
|
Consulting or Advisory Role - Novartis |
Research Funding - Roche (Inst) |
| |
|
Stock and Other Ownership Interests - Anteotech |
Consulting or Advisory Role - Bayer |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Ohara Pharmaceutical |
Speakers' Bureau - Chugai Pharma; Novartis; Ohara Pharmaceutical |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Amgen; Bellicum Pharmaceuticals; Neovii; Novartis; Sanofi |
Speakers' Bureau - Amgen; Bellicum Pharmaceuticals; Bluebird Bio; Gilead Sciences; Jazz Pharmaceuticals; Medac; Miltenyi Biotec; Neovii; SOBI; Takeda |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Abbvie; Illumina; Medac |
Consulting or Advisory Role - Abbvie |
Speakers' Bureau - Agilent; Illumina; Medac |
Travel, Accommodations, Expenses - Abbvie; Agilent |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Bristol-Myers Squibb; DNAtrix; Novartis |
Research Funding - Bristol-Myers Squibb; Novartis |
| |
|
|
Consulting or Advisory Role - AstraZeneca; Novartis |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Celldex; Chinook Therapeutics; Neoleukin Therapeutics; Novartis |
| |
Ana Bento Pereira da Silva |
|
Stock and Other Ownership Interests - Galapagos NV; Roche Canada |
| |
|
|
Stock and Other Ownership Interests - Novartis |
| |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Janssen; Lilly; Novartis; PureTech; Roche/Genentech; SomaNautix |
Research Funding - AstraZeneca |
Expert Testimony - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Novartis; Roche/Genentech |
Other Relationship - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Epizyme; Janssen; Novartis |